PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
